Bill Amendment: IL SB1466 | 2015-2016 | 99th General Assembly

NOTE: For additional amemendments please see the Bill Drafting List

---

Bill Title: PHARMACY-OPIOID ANTAGONIST

Status: 2015-08-07 - Public Act . . . . . . . . . 99-0319 [SB1466 Detail]

Download: Illinois-2015-SB1466-Senate_Amendment_002.html

---

Sen. Melinda Bush

Filed: 4/20/2015

09900SB1466sam002 LRB099 09990 MLM 34014 a
AMENDMENT TO SENATE BILL 1466
AMENDMENT NO. ______. Amend Senate Bill 1466, AS AMENDED,
by replacing everything after the enacting clause with the
following:
"Section 1. This Act may be referred to as Lali's Law.
Section 5. The Pharmacy Practice Act is amended by adding
Section 19.1 as follows:
(225 ILCS 85/19.1 new)
Sec. 19.1. Dispensing of naloxone antidotes.
(a) Due to the recent rise in opioid-related deaths in
Illinois and the existence of an opioid antidote that can
reverse the deadly effects of overdose, the General Assembly
finds that in order to avoid further loss where possible, it is
responsible to allow greater access of such an antidote to
those populations at risk of overdose.

09900SB1466sam002 - 2 - LRB099 09990 MLM 34014 a
(b) Notwithstanding any general or special law to the
contrary, a licensed pharmacist may dispense an opioid antidote
in accordance with written, standardized procedures or
protocols developed by the Department with the Department of
Public Health and the Department of Human Services if the
procedures or protocols are filed at the pharmacy before
implementation and are available to the Department upon
request.
(c) Before dispensing an opioid antidote pursuant to this
Section, a pharmacist shall complete a training program
approved by the Department of Human Services pursuant to
Section 5-23 of the Alcoholism and Other Drug Abuse and
Dependency Act. The training program shall include, but not be
limited to, proper documentation and quality assurance.
(d) For the purpose of this Section, "opioid antidote"
means a dose of naloxone hydrochloride or any other similarly
acting and equally safe drug approved by the United States Food
and Drug Administration.
Section 99. Effective date. This Act takes effect upon
becoming law.".